CDSCO Asks Serum Institute to Revise Protocol for Trivalent Flu-COVID Vaccine Trial
New Delhi: The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has reviewed a proposal submitted by Serum Institute of India Pvt. Ltd. (SIIPL) for a Phase II/III clinical trial of its Trivalent Nanoparticle Influenza Vaccine (NIV) and COVID-Influenza Combination (CIC) Vaccine, and has asked the firm […]